CN100348609C - 治疗代谢紊乱的糖皮质激素受体配基 - Google Patents

治疗代谢紊乱的糖皮质激素受体配基 Download PDF

Info

Publication number
CN100348609C
CN100348609C CNB03814137XA CN03814137A CN100348609C CN 100348609 C CN100348609 C CN 100348609C CN B03814137X A CNB03814137X A CN B03814137XA CN 03814137 A CN03814137 A CN 03814137A CN 100348609 C CN100348609 C CN 100348609C
Authority
CN
China
Prior art keywords
hydroxy
hydrogen
methyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03814137XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1662549A (zh
Inventor
托马斯·W·范格尔顿
詹姆士·T·林克
诺亚·子
菲利普·R·许姆
赖春秋
史蒂文·J·理查兹
皮尔·B·雅各布森
理查德·D·毕晓普
布雷德利·D·盖茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/460,491 external-priority patent/US7141559B2/en
Application filed by Karo Bio AB filed Critical Karo Bio AB
Publication of CN1662549A publication Critical patent/CN1662549A/zh
Application granted granted Critical
Publication of CN100348609C publication Critical patent/CN100348609C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB03814137XA 2002-06-19 2003-06-17 治疗代谢紊乱的糖皮质激素受体配基 Expired - Fee Related CN100348609C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17475002A 2002-06-19 2002-06-19
US10/174,750 2002-06-19
US10/460,491 2003-06-12
US10/460,491 US7141559B2 (en) 2002-06-19 2003-06-12 Glucocorticoid receptor ligands for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
CN1662549A CN1662549A (zh) 2005-08-31
CN100348609C true CN100348609C (zh) 2007-11-14

Family

ID=30002639

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03814137XA Expired - Fee Related CN100348609C (zh) 2002-06-19 2003-06-17 治疗代谢紊乱的糖皮质激素受体配基

Country Status (16)

Country Link
EP (1) EP1551860B1 (enExample)
JP (1) JP4611019B2 (enExample)
KR (1) KR101100826B1 (enExample)
CN (1) CN100348609C (enExample)
AR (1) AR040278A1 (enExample)
AT (1) ATE346082T1 (enExample)
AU (1) AU2003243622B9 (enExample)
CA (1) CA2488535C (enExample)
CY (1) CY1105982T1 (enExample)
DE (1) DE60309909T2 (enExample)
DK (1) DK1551860T3 (enExample)
ES (1) ES2278195T3 (enExample)
PT (1) PT1551860E (enExample)
TW (1) TWI285646B (enExample)
UY (1) UY27862A1 (enExample)
WO (1) WO2004000869A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0514302D0 (en) * 2005-07-12 2005-08-17 Karobio Ab Improved crystalline material
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
CN103957919B (zh) * 2011-09-19 2018-10-16 瑞士苏黎世联邦理工学院 RORγ调节剂
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105693808B (zh) * 2015-11-05 2018-03-16 华润紫竹药业有限公司 一种醋酸乌立妥原料药杂质及其制备方法和作为标准品的用途
FR3055627A1 (fr) * 2016-09-08 2018-03-09 Laboratoire Hra-Pharma Methode de preparation du compose cdb-3877
FR3055626B1 (fr) * 2016-09-08 2018-10-12 Hra Pharma Lab Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489423A1 (de) * 1990-12-06 1992-06-10 Hoechst Aktiengesellschaft Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
US5462933A (en) * 1989-09-14 1995-10-31 Hoechst Aktiengesellschaft Modified bile acid conjugates, and their use as pharmaceuticals
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462933A (en) * 1989-09-14 1995-10-31 Hoechst Aktiengesellschaft Modified bile acid conjugates, and their use as pharmaceuticals
EP0489423A1 (de) * 1990-12-06 1992-06-10 Hoechst Aktiengesellschaft Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIVER-SPECIFIC DRUG TARGETING BY COUPLING TOBILE ACIDS. KRAMER W ET AL.J.BIO.CHEM,Vol.267 No.26. 1992 *

Also Published As

Publication number Publication date
WO2004000869A1 (en) 2003-12-31
CN1662549A (zh) 2005-08-31
AU2003243622A2 (en) 2004-01-06
EP1551860A1 (en) 2005-07-13
UY27862A1 (es) 2004-04-30
AU2003243622B9 (en) 2009-07-16
EP1551860B1 (en) 2006-11-22
CA2488535C (en) 2012-02-07
ATE346082T1 (de) 2006-12-15
AU2003243622A1 (en) 2004-01-06
DK1551860T3 (da) 2007-04-02
DE60309909D1 (de) 2007-01-04
AU2003243622B2 (en) 2009-05-28
TW200410983A (en) 2004-07-01
JP4611019B2 (ja) 2011-01-12
JP2005533807A (ja) 2005-11-10
TWI285646B (en) 2007-08-21
AR040278A1 (es) 2005-03-23
ES2278195T3 (es) 2007-08-01
CA2488535A1 (en) 2003-12-31
DE60309909T2 (de) 2007-06-21
PT1551860E (pt) 2007-02-28
CY1105982T1 (el) 2011-04-06
KR101100826B1 (ko) 2012-01-02
KR20050016588A (ko) 2005-02-21

Similar Documents

Publication Publication Date Title
CN100348609C (zh) 治疗代谢紊乱的糖皮质激素受体配基
CN103619866B (zh) C4-一甲基三萜系化合物的衍生物及其使用方法
AU2025202679A1 (en) Modulators of g-protein coupled receptors
UA122035C2 (uk) Агоністи рецептора glp-1 та їх застосування
CN105820160A (zh) 细胞粘着调节剂
HK1047580B (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes
WO2008040974A1 (en) Indoles for use as dpp-iv inhibitors
JP2023546125A (ja) Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用
JP2002503666A (ja) グルココルチコイド選択性消炎剤
FI89055C (fi) Foerfarande foer framstaellning av nya androstan-17-karboxylsyraestrar
JPS6361314B2 (enExample)
US7141559B2 (en) Glucocorticoid receptor ligands for the treatment of metabolic disorders
KR20010075511A (ko) 지질대사 장애 치료용으로 사용되는, 담즙산과 결합된프로판올아민 유도체
CN1902195B (zh) 细胞粘着调节剂
EP0976720A1 (en) Propanolamine derivatives
AU751708B2 (en) Pregnane glucuronides
TW202542125A (zh) 烯烴類化合物、其製備方法及其在醫藥上的應用
FR2806723A1 (fr) DERIVES D'ACIDE 8-OXO-5,8-DIHYDRO-6H-DIBENZO [a,g] QUINOLIZINE-13-PROPANOIQUE , LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
HK1227405A1 (en) Modulators of cellular adhesion
HK1095815B (en) Modulators of cellular adhesion
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
HK1189894B (en) C4-monomethyl triterpenoid derivatives and methods of use thereof
HK1189894A (en) C4-monomethyl triterpenoid derivatives and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071114

Termination date: 20120617